Actively Recruiting
Study on Treatment Persistence of Abemaciclib in Women with High-Risk HRHER2- Early Breast Cancer
Led by Institut fuer Frauengesundheit · Updated on 2026-05-14
200
Participants Needed
1
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
This observational study focuses on patients with high-risk hormone receptor-positive HR and HER2-negative early breast cancer. Researchers aim to evaluate how consistently these patients continue taking abemaciclib six months after starting therapy. The study involves a retrospective analysis of treatment data to better understand patient adherence to abemaciclib in this specific breast cancer group. Participants include female patients aged 18 or older who have a confirmed diagnosis of HRHER2- early breast cancer without distant metastasis. All participants must have been prescribed abemaciclib therapy between January 1, 2023, and June 30, 2025, following the official product guidelines. The study does not involve any new treatments but observes patients receiving abemaciclib as part of their routine care. During the study, researchers will review existing therapy data to measure the persistence rate of abemaciclib use at six months after the therapy start. There are no additional treatments or interventions required. The study monitors adherence through retrospective data collection and does not involve direct patient visits or interventions. The study is sponsored by the Institut fuer Frauengesundheit and is expected to continue until March 2027.
CONDITIONS
Brief Title
Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
Research Team
S
Sponsor's study office
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here